What are Monoclonal Antibodies?

Monoclonal antibodies (mAbs) are immunoglobulins that exhibit a high level of specificity toward a single antigen or epitope. These antibodies are produced from a single B-cell clone, resulting in identical immunoglobulins with precise binding capabilities.

Monoclonal Antibody Mechanisms of Action

Monoclonal antibodies exert their mechanisms of action by specifically binding to target antigens or epitopes on cells or molecules. This targeted binding can block signaling pathways, interfere with protein-protein interactions or prevent receptor-ligand interactions, leading to the modulation of cellular function and immune response. mAbs structures can also be engineered to serve as carriers for delivering therapeutic agents (antibody-drug conjugates; ADCs) directly to target cells, enabling selective and precise treatment delivery. Furthermore, specific mAbs can trigger immune-mediated cell toxicity or disrupt tumor blood vessel formation, inhibiting of tumor growth.

Types of Monoclonal Antibodies

Naked Monoclonal Antibodies

• Naked mAbs function independently without any attached drugs or radioactive materials, operating solely based on their inherent properties

Conjugated Monoclonal Antibodies

• Conjugated mAbs have been linked or combined with a chemotherapy drug or a radioactive particle

Bispecific Monoclonal Antibodies

• Bispecific mAbs are specialized antibody molecules designed to bind to two different target proteins simultaneously. For instance, blinatumomab binds to the CD19 protein (found in certain leukemia and lymphoma cells) and to the CD3 protein present in T cells. This dual binding mechanism brings cancer and immune cells together, potentially leading to immune system-mediated attacks on cancer cells.

Types of Monoclonal Antibody Development Methods

Hybridoma

The utilization of hybridoma technology is a widely employed approach to produce mAbs. This mAb development process typically includes immunization of animals with the target antigen, isolation of antibody-producing B-cells, fusion of B-cells with myeloma cells to form hybridoma cells, screening and selection of desired antibody-producing hybridomas and subsequent culturing and harvesting of mAbs from the selected hybridoma clones. During the development process, antibody characterization is crucial to assess the antibodies’ quality, potency and specificity.

Phage Display

Phage display is a technique that involves expressing antibody fragments on the surface of bacteriophages to display human antibody fragments. These phages can then be screened for their binding affinity to a specific target antigen, allowing the identification of high-affinity antibodies.

Single B Cell

Single B cell technology enables the production of mAbs with native heavy and light chain pairings by directly amplifying Ig genes from individual human B cells. These genes are expressed in cell culture, preserving the natural antibody diversity. This method increases the likelihood of generating mAbs that recognize complex, conformational epitopes that are difficult to mimic in vivo.

Recombinant Antibodies

Recombinant utilizes genetic engineering that encode specific antibodies. There genes are introduced into expression systems, such as bacteria, yeast, or mammalian cells. Recombinant mAb creates custom antibodies by allowing the generation of hybrid antibodies structures with unique characteristics.

Chimeric Antibodies

Chimeric mAbs are molecules composed of segments fused from different species. For example, the Fc or constant domains (scaffolding) could be human-derived, and the binding (variable) region could be derived from a mouse.

Humanized Antibodies

Humanized antibody production utilizes immunized in vivo models, such as mice, with target antigens. These antibodies are then mostly human in sequence, with only the antigen-binding sites (complementarity-determining regions) from the mouse. This creates human mAbs with a higher degree of diversity and affinity.

Ensuring Product Quality Attributes

Despite the method of development, mAbs can exhibit heterogeneity due to enzymatic and nonenzymatic modifications, such as incomplete disulfide bond formation, glycosylation, N-terminal cyclization, C-terminal lysine processing, deamidation, isomerization, oxidation and other post-translational modifications. When developing mAbs for therapeutic use, it is important to consider and test binding affinity, stability, purity and potency throughout the production process.

Applications of Monoclonal Antibodies

• mAbs serve as indispensable tools in laboratory research. They are used in analytics and chemical research, including immunoassays, research tools, protein purification and drug development – these processes play a critical role in tissue and blood typin.
• mAbs are regularly used in diagnostics such as pregnancy testing, screening and monitoring of cancers and analysis of hormonal disorders.
• mAbs therapeutics can potentially minimize side effects and improve patient outcomes. mAb Treatments include complications of viral infections, cancer, radioimmunotherapy, treatment of asthma, AIDS and COVID-19.
  • Examples of mAbs in treatment include Rituximab, Trastuzumab, Pembrolizumab, Adalimumab, Bevacizumab and Eculizumab, which are used for the treatment of various conditions such as cancer, autoimmune diseases, inflammatory disorders and rare blood disorders.

Advancements in Monoclonal Antibodies

Cell Line Development

Cell line development plays a crucial role in the future of antibody engineering. It enables the generation of stable cell lines to produce engineered recombinant antibodies with improved properties, such as enhanced affinity, specificity and stability. However, this process is cumbersome and ripe for automation and innovation targeting process improvements that speed up development and manufacturing while ensuring critical quality attributes are not adversely impacted.

Combination Therapies

Combination therapies are emerging as a promising approach, where mAbs are used in combination with other therapies such as chemotherapy, immune checkpoint inhibitors or targeted small molecules.

Personalized Medicine and Biomarkers

The future of mAbs also involves personalized medicine and biomarkers, where specific patient characteristics and biomolecular signatures are utilized to tailor antibody treatments. This approach allows for individualized dosing, treatment selection and improved patient outcomes.

Novel Applications in Imaging

Furthermore, there is a growing interest in utilizing mAbs in novel applications such as imaging. Antibodies can be engineered or conjugated with imaging agents to enable precise disease detection, imaging of specific targets and monitoring of treatment response, opening new avenues for early diagnosis and therapeutic monitoring.

recent-articles